Day One Biopharmaceuticals, Inc. (DAWN)

DAWN Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-95.5	-188.92	-142.18	-70.65	-40.51
Depreciation & Amortization	2.03	0.38	0.53	0.2	0.16
Asset Writedown & Restructuring Costs	55	3	-	8	-
Loss (Gain) From Sale of Investments	-6.39	-10.08	-2.03	-	-
Stock-Based Compensation	48.26	39.34	27.24	13.32	0.53
Other Operating Activities	-108	-	-	-2.11	26.69
Change in Accounts Receivable	-13.88	-	-	-	-
Change in Inventory	-3.24	-	-	-	-
Change in Accounts Payable	0.69	2.32	-1.48	1.54	0.13
Change in Unearned Revenue	4.79	-	-	-	-
Change in Other Net Operating Assets	38.13	7.1	8.05	1.15	-0.49
Operating Cash Flow	-78.11	-146.85	-109.87	-48.54	-13.49
Capital Expenditures	-2.17	-0.22	-0.03	-	-0.09
Sale (Purchase) of Intangibles	-72.1	-3	-	-8	-
Investment in Securities	-264.73	131.6	-255.05	-	-
Other Investing Activities	108	-	-	-	-
Investing Cash Flow	-230.99	128.38	-255.07	-8	-0.09
Issuance of Common Stock	182.35	164	165.9	167.36	-
Other Financing Activities	20.94	-	-	-	-
Financing Cash Flow	203.29	164	165.9	297.12	29.98
Net Cash Flow	-105.82	145.52	-199.05	240.58	16.4
Free Cash Flow	-80.28	-147.08	-109.9	-48.54	-13.58
Free Cash Flow Margin	-61.21%	-	-	-	-
Free Cash Flow Per Share	-0.86	-1.84	-1.68	-1.31	-2.46
Cash Income Tax Paid	1.9	-	-	-	-
Levered Free Cash Flow	-133.99	-82.72	-56.86	-37.01	-9.6
Unlevered Free Cash Flow	-133.99	-82.72	-56.86	-37.01	-9.58
Change in Net Working Capital	-22.66	-9.57	-7.21	-2.94	1.56

Source: S&P Capital IQ. Standard template. Financial Sources.